Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytokine modulators for allergic diseases.

P J Barnes1

  • 1Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College, London, UK. p.j.barnes@ic.ac.uk

Current Opinion in Allergy and Clinical Immunology
|April 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucocorticoid resistance in asthma.

American journal of respiratory and critical care medicine·1995
Same author

Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

The Journal of experimental medicine·1995
Same author

Inhibition of macrophage inflammatory protein-1 alpha expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages.

Journal of immunology (Baltimore, Md. : 1950)·1995
Same author

Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.

Molecular pharmacology·1995
Same author

Corticosteroid inhibition of macrophage inflammatory protein-1 alpha in human monocytes and alveolar macrophages.

The American journal of physiology·1995
Same author

Cytokine expression in normal, atopic, and asthmatic subjects using the combination of sputum induction and the polymerase chain reaction.

Thorax·1995

Targeting specific cytokines, like interleukin-5 and interleukin-13, shows promise for treating allergic diseases such as asthma. Inhibitory cytokines are also being explored for therapeutic benefits in managing inflammation.

Area of Science:

  • Immunology and Molecular Biology
  • Inflammation Research
  • Allergic Disease Pathogenesis

Background:

  • Cytokines are key mediators in the inflammatory processes underlying allergic diseases.
  • Specific T helper 2 (Th2) cytokines, including interleukin-5 (IL-5), interleukin-13 (IL-13), and interleukin-9 (IL-9), are implicated in allergic responses.
  • Tumor necrosis factor-alpha (TNF-α) also contributes to inflammation in allergic conditions.

Purpose of the Study:

  • To review the role of specific cytokine inhibitors in the treatment of allergic diseases.
  • To discuss the therapeutic potential of targeting Th2 cytokines (IL-5, IL-13, IL-9) and TNF-α.
  • To explore the consideration of inhibitory cytokines like interleukin-10 (IL-10), interferons (IFNs), and interleukin-12 (IL-12) in managing allergic conditions.

Main Methods:

Related Experiment Videos

  • Review of current research on cytokine inhibition in allergic diseases.
  • Discussion of the mechanisms of action for various cytokine inhibitors.
  • Analysis of the therapeutic implications of targeting specific inflammatory pathways.

Main Results:

  • Inhibitors targeting Th2 cytokines (IL-5, IL-13, IL-9) are under development for asthma and allergic diseases.
  • Inhibition of TNF-α is also being investigated as a treatment strategy.
  • The potential use of IL-10, IFNs, and IL-12 as therapeutic agents in allergic diseases is being considered.

Conclusions:

  • Targeting key cytokines involved in allergic inflammation offers promising therapeutic avenues.
  • Cytokine inhibition represents a significant area of development for managing asthma and other allergic conditions.
  • Further research into both inhibitory and targeted cytokines may lead to novel treatment strategies.